Autism Spectrum Disorder Symptom Profiles in Fragile X Syndrome, Angelman Syndrome, Tuberous Sclerosis Complex and Neurofibromatosis Type 1.

Autism Spectrum Disorder Symptom Profiles in Fragile X Syndrome, Angelman Syndrome, Tuberous Sclerosis Complex and Neurofibromatosis Type 1.

Publication date: Oct 12, 2024

Studying Autism Spectrum Disorder (ASD) heterogeneity in biologically homogeneous samples may increase our knowledge of ASD etiology. Fragile X syndrome (FXS), Angelman syndrome (AS), Tuberous Sclerosis Complex (TSC), and Neurofibromatosis type 1 (NF1) are monogenic disorders with high a prevalence of ASD symptomatology. This study aimed to identify ASD symptom profiles in a large group of children and adolescents (0;9-28 years) with FXS, AS, TSC, and NF1. Data on ASD symptomatology (Autism Diagnostic Observation Scale (ADOS-2) & Social Responsiveness Scale (SRS-2)) were collected from children and adolescents with FXS (n = 54), AS (n = 93), TSC (n = 112), and NF1 (n = 278). To identify groups of individuals with similar ASD profiles, we performed two latent profile analyses. We identified a four-profile model based on the ADOS-2, with a (1) ‘Non-spectrum symptom profile’, (2) ‘Social Affect symptom profile’, (3)’Restricted/Repetitive Behaviors symptom profile’, and (4)’ASD symptom profile’. We also identified a four-profile model based on the SRS, with a (1)’Non-clinical symptom profile’, (2)’Mild symptom profile’, (3)’Moderate symptom profile’, and (4)’Severe symptom profile’. Although each syndrome group exhibited varying degrees of severity, they also displayed heterogeneity in the profiles in which they were classified. We found distinct ASD symptom profiles in a population consisting of children and adolescents with FXS, AS, TSC, and NF1. Our study highlights the importance of a personalized approach to the identification and management of ASD symptoms in rare genetic syndromes. Future studies should aim to include more domains of functioning and investigate the stability of latent profiles over time.

Open Access PDF

Concepts Keywords
Angelman Angelman syndrome
Autism Autism spectrum disorder
Genetic Fragile X syndrome
Sclerosis Latent profile analysis
Neurofibromatosis type 1
Tuberous sclerosis complex

Semantics

Type Source Name
disease MESH Autism Spectrum Disorder
disease MESH Tuberous Sclerosis Complex
disease MESH Neurofibromatosis Type 1
disease MESH etiology
disease MESH Fragile X syndrome
disease MESH Angelman syndrome
disease MESH Autism
disease MESH syndrome
disease MESH Neurodevelopmental Disorders
disease MESH Neurofibromatosis
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Sirolimus
drug DRUGBANK Coenzyme M
disease MESH epilepsy
drug DRUGBANK Iron
drug DRUGBANK Succimer
disease MESH Asperger’s disorder
disease MESH clinical relevance
drug DRUGBANK Trestolone
drug DRUGBANK Flunarizine
drug DRUGBANK Ademetionine
disease MESH genetic disorders
disease MESH privacy
drug DRUGBANK Etoperidone
drug DRUGBANK Indoleacetic acid
disease MESH mood disorders
disease MESH Comorbidity
disease MESH Malformations
disease MESH Intellectual Disability
pathway REACTOME Reproduction
pathway REACTOME Translation
drug DRUGBANK L-Isoleucine
disease MESH Rare Diseases
drug DRUGBANK Adenosine
drug DRUGBANK Butoconazole
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Valrubicin
disease MESH Developmental Disabilities
disease MESH anxiety
pathway REACTOME Metabolism

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *